News

I’m raising money in memory of my beloved, beautiful mum, Georgina, who sadly passed away in August 2024 following a long battle with AL Amyloidosis - a rare…

Amyloidosis Market Global Outlook, Country Deep-Dives & Strategic Opportunities (2024-2033) Market size (2024): USD 1.2 billion · Forecast (2033): 1.20 Billion…

Cardiac amyloidosis (CA) represents an increasingly recognized but historically underdiagnosed cause of restrictive cardiomyopathy and heart failure. CA is now…

We’re proud to announce Worcestershire Acute Hospitals NHS Trust as our Q1 2026 Network Spotlight winner! Led by Dr. David Wilson,…

The European Commission has expanded the indication of Amvuttra (vutrisiran) to include adults with ATTR amyloidosis with cardiomyopathy, or heart damage (ATTR-CM…

In hopes of improving outcomes of amyloidosis, a rare but serious disease caused by the buildup of abnormal amyloid deposits, The College of American Pathologists (…

Kristen Hsu, ARC’s Executive Director of Research, shared the latest updates on ATTR (transthyretin amyloidosis) clinical trials and what these developments mean…

AbstractBACKGROUND:Transthyretin amyloid cardiomyopathy (ATTR-CM) causes a restrictive cardiomyopathy resulting in heart failure (HF). Signaling pathways associated…

Treatments that target the transthyretin (TTR) protein, either by stabilizing it or reducing its production, were associated with about a one-third lower risk of…

Chicago, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The global amyloidosis therapeutics market was valued at 2.95 billion in 2024 and is expected to reach US$ 6.37 billion…